UNC, Kerr Drug to Study PGx Program for Plavix | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Drug store chain Kerr Drug and the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill plan to investigate the feasibility of implementing a pharmacogenomic program at the community pharmacy level directed at Plavix (clopidogrel).

Under the six-month study announced today, the partners will jointly develop a protocol, evaluate physician and patients opinions, and research reimbursement challenges and regulatory requirements to such a program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."